This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Gilead Hep C Drug Launch Threatened by Price Concerns

Updated with analyst defense of Gilead Sciences

The top medical officer for pharmacy benefits manager Express Scripts  (ESRX) expressed concerns about high pricing for the new crop of hepatitis C pills, most notably Gilead Sciences'  (GILD) Sovaldi, according to a Bloomberg story Tuesday.

Solvadi may be pitted against other hepatitis C therapies, Express Scripts' chief medical officer said, and "tough formulary decisions" will be made. 

Shares of Gilead are down 4.5% to $71.84 after the Bloomberg story hit the wires. Shares of Abbvie, on the other hand, are up 4.5% to $53.51. 

The FDA approved Gilead's Sovaldi on Friday and the drug is priced at $1,000 per pill, or $84,000 for a 12-week course of therapy.

Abbvie's Hep C regimen is expected to be approved next year. If the company prices the drug cocktail right, it may gain extra market share and revenue, based on the Express Scripts comments today.

Shares of Enanta Pharma (ENTA), which contributes a drug to the Abbvie regimen and will receive royalties on sales, are up 18% to $35.10.

Here are some tweets from Bloomberg reporter Drew Armstrong on the interview with Express Scripts' chief medical officer:




$ESRX CMO: Says convenience won't = formulary coverage, all other things being equal. 1-pill-day not enough to trump price. Drew Armstrong (@ArmstrongDrew) December 10, 2013

ISI Group analyst Mark Schoenebaum sent an email to clients noting that Express Script covers approximately 100 million people and is estimated in 2013 to fill about 1.5 billion drug prescriptions, or 38% of the total presciptions filled in the U.S.

Schoenebaum also offered a defense of Gilead:
While competition in GT1 patients is intense, GILD is meaningfully ahead (years) of other companies in approval of a regimen to treat GT2/3 patients.  Therefore, Express Scripts would appear to lack the ability to block GILD's regimen in GT2/3 patients (~20% of hepatitis C patients in the US) at least in the near term (unlikely an issue in 2014).

While the efficacy of both GILD and ABBV regimens in genotype 1 (~75% of hepatitis C patients in the US) looks good, there are differences between regimens which may make pitting the two companies against each other more difficult - the # of pills for GILD's regimen are significantly less, GILD's regimen includes a nuc which has a higher barrier for resistance, ABBV's regimen includes ritonavir which may interact with other drugs patients may be taking, etc.  Therefore, a big price differential would likely be necessary to block GILD's regimen.  In a two-player market (before other competitors reach the market), whether ABBV would be willing to take a large price cut is not clear.  Thus, the larger risk to price could be pushed out until ~2017 when other competitors are able to reach the market.

We do not yet know how GILD will price in GT1 with its regimen combining sofosbuvir with an NS5a (and perhaps ribavirin) but also potentially being shorter (8 wks rather than 12 wks) for many patients.  Note, the cost of currently marketed hep C therapy (Incivek/Victrelis with peginterferon and ribavirin) in genotype 1 is ~$80-100K.


Stock quotes in this article: GILD, ABBV, ENTA, ESRX 
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs